FDA OKs presurgical use of Roche's breast cancer drug Perjeta

10/1/2013 | Bloomberg · Reuters

The FDA approved the use of Roche Holding's Perjeta, or pertuzumab, to reduce tumor size before surgery in patients with HER2-positive, early-stage breast cancer. The drug would be used in combination with Roche's older breast cancer treatment Herceptin and chemotherapy. The approval makes Perjeta the first presurgical treatment for breast cancer.

View Full Article in:

Bloomberg · Reuters

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC